HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.

Abstract
Gene-directed enzyme prodrug therapy (GDEPT) aims to achieve highly selective tumor-cell killing through the use of tumor-tropic gene delivery vectors coupled with systemic administration of otherwise inert prodrugs. Nitroaromatic prodrugs such as CB1954 hold promise for GDEPT as they are readily reduced to potent DNA alkylating agents by bacterial nitroreductase enzymes (NTRs). Transfection with the nfsB gene from Escherichia coli can increase the sensitivity of tumor cells to CB1954 by greater than 1000-fold. However, poor catalytic efficiency limits the activation of CB1954 by NfsB at clinically relevant doses. A lack of flexible, high-throughput screening technology has hindered efforts to discover superior NTR candidates. Here we demonstrate how the SOS chromotest and complementary screening technologies can be used to evaluate novel enzymes that activate CB1954 and other bioreductive and/or genotoxic prodrugs. We identify the major E. coli NTR, NfsA, as 10-fold more efficient than NfsB in activating CB1954 as purified protein (k(cat)/K(m)) and when over-expressed in an E. coli nfsA(-)/nfsB(-) gene deleted strain. NfsA also confers sensitivity to CB1954 when expressed in HCT-116 human colon carcinoma cells, with similar efficiency to NfsB. In addition, we identify two novel E. coli NTRs, AzoR and NemA, that have not previously been characterized in the context of nitroaromatic prodrug activation.
AuthorsG A Prosser, J N Copp, S P Syddall, E M Williams, J B Smaill, W R Wilson, A V Patterson, D F Ackerley
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 79 Issue 5 Pg. 678-87 (Mar 01 2010) ISSN: 1873-2968 [Electronic] England
PMID19852945 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright2009 Elsevier Inc. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Aziridines
  • Escherichia coli Proteins
  • Prodrugs
  • tretazicar
  • NfsA protein, E coli
  • Nitroreductases
Topics
  • Adenocarcinoma (drug therapy, genetics, pathology)
  • Antineoplastic Agents (metabolism, therapeutic use)
  • Aziridines (metabolism, therapeutic use)
  • Cell Survival (drug effects)
  • Colonic Neoplasms (drug therapy, genetics, pathology)
  • Drug Screening Assays, Antitumor
  • Escherichia coli (enzymology, genetics)
  • Escherichia coli Proteins (metabolism)
  • Gene Silencing
  • Genetic Therapy
  • Humans
  • Kinetics
  • Nitroreductases (metabolism)
  • Prodrugs (metabolism, therapeutic use)
  • SOS Response, Genetics (drug effects, genetics)
  • Transfection
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: